480 related articles for article (PubMed ID: 23291040)
1. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
Sagaster V; Ludwig H; Kaufmann H; Odelga V; Zojer N; Ackermann J; Küenburg E; Wieser R; Zielinski C; Drach J
Leukemia; 2007 Jan; 21(1):164-8. PubMed ID: 17096015
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of chromosomal aberrations in multiple myeloma.
Nahi H; Sutlu T; Jansson M; Alici E; Gahrton G
J Intern Med; 2011 Feb; 269(2):137-47. PubMed ID: 21158983
[TBL] [Abstract][Full Text] [Related]
4. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
5. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains.
Chang H; Trieu Y; Qi X; Jiang NN; Xu W; Reece D
Leuk Res; 2011 Jan; 35(1):95-8. PubMed ID: 20537706
[TBL] [Abstract][Full Text] [Related]
6. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
Avet-Loiseau H; Soulier J; Fermand JP; Yakoub-Agha I; Attal M; Hulin C; Garderet L; Belhadj K; Dorvaux V; Minvielle S; Moreau P;
Leukemia; 2010 Mar; 24(3):623-8. PubMed ID: 20072152
[TBL] [Abstract][Full Text] [Related]
7. Genomic stratification of multiple myeloma treated with novel agents.
Jiang A; Reece D; Chang H
Leuk Lymphoma; 2012 Feb; 53(2):202-7. PubMed ID: 21823830
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment.
An G; Acharya C; Deng S; Yi S; Xu Y; Qin X; Sui W; Li Z; Shi L; Zang M; Feng X; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Tai YT; Qiu L
Exp Hematol; 2015 Mar; 43(3):168-176.e2. PubMed ID: 25462022
[TBL] [Abstract][Full Text] [Related]
9. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Dimopoulos MA; Kastritis E; Christoulas D; Migkou M; Gavriatopoulou M; Gkotzamanidou M; Iakovaki M; Matsouka C; Mparmparoussi D; Roussou M; Efstathiou E; Terpos E
Leukemia; 2010 Oct; 24(10):1769-78. PubMed ID: 20739955
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma.
Minarik J; Scudla V; Bacovsky J; Zemanova M; Pika T; Ordeltova M; Langova K
Neoplasma; 2010; 57(1):8-14. PubMed ID: 19895166
[TBL] [Abstract][Full Text] [Related]
12. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
13. Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
Vangsted AJ; Klausen TW; Abildgaard N; Andersen NF; Gimsing P; Gregersen H; Nexø BA; Vogel U
Ann Hematol; 2011 Oct; 90(10):1173-81. PubMed ID: 21347685
[TBL] [Abstract][Full Text] [Related]
14. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
15. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
Nemec P; Zemanova Z; Greslikova H; Michalova K; Filkova H; Tajtlova J; Kralova D; Kupska R; Smetana J; Krejci M; Pour L; Zahradova L; Sandecka V; Adam Z; Buchler T; Spicka I; Gregora E; Kuglik P; Hajek R
Biol Blood Marrow Transplant; 2010 Apr; 16(4):548-54. PubMed ID: 20005965
[TBL] [Abstract][Full Text] [Related]
16. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Badros A; Gahres N
Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432
[No Abstract] [Full Text] [Related]
18. Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group.
Walter-Croneck A; Grzasko N; Soroka-Wojtaszko M; Jurczyszyn A; Torosian T; Rymko M; Nowicki A; Druzd-Sitek A; Lech-Maranda E; Madro E; Zielinska P; Grygoruk-Wisniowska I; Blonska D; Usnarska-Zubkiewicz L; Potoczek S; Iskierka E; Masternak A; Holojda J; Dawidowska D; Gawron L; Barchnicka A; Olszewska-Szopa M; Rybicka M; Gontarska A; Jachalska A; Rzepecki P; Subocz E; Boguradzki P; Charlinski G; Dzierzak-Mietla M; Wisniewska-Piaty K; Swistek W; Kopacz A; Blajer-Olszewska B; Swiderska A; Dmoszynska A
Leuk Res; 2014 Jul; 38(7):788-94. PubMed ID: 24862794
[TBL] [Abstract][Full Text] [Related]
19. Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
Krejci M; Gregora E; Straub J; Minarik J; Scudla V; Adam Z; Krivanova A; Pour L; Zahradova L; Buchler T; Mayer J; Hajek R
Ann Hematol; 2011 Dec; 90(12):1441-7. PubMed ID: 21380511
[TBL] [Abstract][Full Text] [Related]
20. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
Satoh M; Oguro R; Yamanaka C; Takada K; Matsuura Y; Akiba T; Aotsuka N; Tani Y; Wakita H
J Pharm Pharm Sci; 2011; 14(1):78-89. PubMed ID: 21501555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
